Nanovibronix (FEED) and The Competition Head to Head Review

Nanovibronix (NASDAQ:FEED) is one of 29 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its rivals? We will compare Nanovibronix to similar businesses based on the strength of its risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Nanovibronix and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-275.12%	-24.78%	-19.24%
Nanovibronix Competitors	-672.41%	-133.75%	-59.01%

Institutional and Insider Ownership

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 1.4% of Nanovibronix shares are held by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Nanovibronix and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1	0	0	0	1.00
Nanovibronix Competitors	77	77	156	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 43.22%. Given Nanovibronix’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Nanovibronix has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Nanovibronix and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nanovibronix	$2.69 million	-$3.70 million	-0.07
Nanovibronix Competitors	$59.55 million	-$32.15 million	4.35

Nanovibronix’s rivals have higher revenue, but lower earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Nanovibronix has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Nanovibronix’s rivals have a beta of 1.76, meaning that their average share price is 76% more volatile than the S&P 500.

Summary

Nanovibronix rivals beat Nanovibronix on 8 of the 13 factors compared.

Nanovibronix Company Profile

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.